Gene therapy for blood cancer shows 73 per cent response rate in clinical trials, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom ‘B-cell’ tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies., Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom ‘B-cell’ tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies., , Read More

Leave a Reply

Your email address will not be published. Required fields are marked *